Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials.

Journal of cancer research and clinical oncology - 1 Mar 2020

Luo Jing, Dai Xinchi, Hu Hua, Chen Jie, Zhao Lujun, Yang Changyong, Sun Jifeng, Zhang Lianmin, Wang Qian, Xu Shilei, Xu Yue, Liu Ningbo, Ying Guoguang, Wang Ping

Abstract excerpt

PROPOSE: Poly (ADP-ribose) polymerase 1 inhibitors were originally investigated as anti-cancer therapeutics with BRCA1/2 genes mutation. Here, we investigate the effectiveness of a novel PARP1 inhibitor fluzoparib, for enhancing the radiation sensitivity of NSCLC cells lacking BRCA1/2 mutation. METHODS: We used MTS assays, western blotting, colony formation assays, immunofluorescence staining, and flow cytometry...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis
Share to BRCA1 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA2 Protein

Share to Carcinoma, Non-Small-Cell Lung

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Radiation-Sensitizing Agents

Share to Radiation Tolerance

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 31786739
DOI: 10.1007/s00432-019-03097-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials.PMID 31786739Read ↗

BLM helicase inhibition synergizes with PARP inhibition to improve the radiosensitivity of olaparib resistant non-small cell lung cancer cells by inhibiting homologous recombination repairSemantic proximity Read ↗

Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors.Semantic proximity Read ↗

PARP inhibitor niraparib as a radiosensitizer promotes antitumor immunity of radiotherapy in EGFR-mutated non-small cell lung cancer.Semantic proximity Read ↗

PARP-1 genetic polymorphism associated with radiation sensitivity of non-small cell lung cancer.Semantic proximity Read ↗

Clinical translation for targeting DNA damage repair in non-small cell lung cancer: a reviewSemantic proximity Read ↗

Targeting the DNA Damage Response Machinery for Lung Cancer TreatmentSemantic proximity Read ↗

Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation TherapySemantic proximity Read ↗

DNA Repair Enzyme Poly(ADP-Ribose) Polymerase 1/2 (PARP1/2)-Targeted Nuclear Imaging and RadiotherapySemantic proximity Read ↗

PARP inhibitors combined with radiotherapy: are we ready?Semantic proximity Read ↗

Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cellsSemantic proximity Read ↗

The Prognostic and Therapeutic Potential of DNA Damage Repair Pathway Alterations and Homologous Recombination Deficiency in Lung CancerSemantic proximity Read ↗

PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non‐small‐cell lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.